FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress

WOBURN, Mass., Aug. 18, 2011 /PRNewswire/ -- CBI is pleased to announce the full agenda for its industry-leading, 14th Annual Registries and Post-Approval Studies Congress, being held September 20-22, 2011 in Philadelphia, PA. The program, sponsored by REGISTRAT-MAPI, boasts an impressive speaker lineup from Celgene, Covidien, FDA, Forest, Ironwood Pharmaceuticals, Merck, NIH, Pfizer, Takeda Europe and many more.

Attendees have the opportunity to customize their congress experience by choosing between breakout sessions, concurrent tracks and participating in interactive panel discussions. Session highlights include:

  • Driving Value in Research by Designing, Implementing and Improving Patient Registries
  • Optimizing Post-Marketing Requirements and REMS
  • Developing Strategies to Benefit Sponsor and Regulatory Authorities
  • Complying with U.S., EU and Canadian Post-Approval Requirements
  • Responding to Increased Payer Requirements to Support Reimbursement Decisions
  • Maximizing the Value of Registries and Other Post-Approval Studies

Industry leaders will be afforded the exclusive opportunity to participate in the Invitation-Only Post-Approval Executive Summit hosted by REGISTRAT-MAPI. This 5th Annual Summit provides a unique forum for senior-level executives involved in post-approval studies, including clinical, medical, safety and regulatory to address the strategic issues they face.

CBI's Post-Approval Studies series is the industry's premier source for cutting-edge content and unparalleled programming related to post-approval studies. For more information on the conference or to view the entire agenda, please visit http://www.cbinet.com/postapproval.

About CBI:

CBI, a subsidiary of Advanstar, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. For more information, please visit http://www.cbinet.com.

About REGISTRAT-MAPI, Global Foundation Sponsor:

REGISTRAT-MAPI provides strategic and operational solutions for our clients in the design and implementation of Late Phase studies. REGISTRAT-MAPI is the pharmaceutical industry's largest global CRO dedicated exclusively to real-world clinical research. With more than 250 experienced professionals, REGISTRAT-MAPI has served the pharmaceutical and medical device industries for more than 20 years. For more information, please visit http://www.registratmapi.com.

For additional information or media inquiries, please contact Emily Forest, CBI Marketing Manager, at 339-298-2156 or Amy Wynn, REGISTRAT-MAPI Manager, Global Marketing, at 215-568-0121.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE CBI

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.